10 Results for "

Internalization of PD-L1

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "Internalization of PD-L1" in MCE Product Catalog:

Cat. No.: HY-P10439
CAS No.: 2349354-64-7
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

CVRARTR is a programmed cell death ligand-1 (PD-L1) antagonist with a KD of 281 nM. CVRARTR induces the internalization of PD-L1 and downregulates PD-L1 on the cell surface. CVRARTR restores cytokine secretion and T cell proliferation in cell CT26. CVRARTR exhibits antitumor efficacy against in CT26 homograft mouse model. CVRARTR can be used in melanoma research .
loading...
    loading...
Cat. No.: HY-144258
CAS No.: 2499965-12-5
Purity:  99.85%
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of PD-1/PD-L1 interactions, with an IC50 of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 .
loading...
    loading...
Cat. No.: HY-P990690
CAS No.: 2407760-40-9
Synonyms: MEDI-5752

Target:  

PD-1/PD-L1 CTLA-4

Research Areas:  

Cancer

Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 + T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 + B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .
loading...
    loading...
Cat. No.: HY-152240
CAS No.: 2665734-13-2
Purity:  99.96%
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-1/PD-L1-IN-29 (S4-1) is a potent PD-1/PD-L1 inhibitor with an IC50 value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity .
loading...
    loading...
Cat. No.: HY-179447
CAS No.: 3104751-99-4
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-L1-IN-8 is a PD-L1 inhibitor (IC50 = 0.89 nM). PD-L1-IN-8 shows low CYP inhibition and minimal hERG activity. PD-L1-IN-8 can be used for the study of colon cancer .
loading...
    loading...
Cat. No.: HY-163958
CAS No.: 3024733-03-4
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-L1-IN-7 (compound CB31) is an inhibitor of PD-L1, which can induce PD-L1 internalization and PD-L1 retention in cells. PD-L1-IN-7 can inhibit the interaction of PD-1/PD-L1 (IC50: 0.2 nM), change the glycosylation pattern, and promote PD-L1 degradation. PD-L1-IN-7 can also enhance T cell infiltration, amplify T cell function and the ability to kill tumor cells .
loading...
    loading...
Cat. No.: HY-161604
CAS No.: 3034161-55-9
Target:  

HBV PD-1/PD-L1

HBV/HDV-IN-1 (Compd 122) is a HBV, HDV and PD-1/PD-L1 inhibitor, with EC50 values of 8 nM for T cell activation and 35 nM for PD-L1 internalization .
loading...
    loading...
Cat. No.: HY-184989
PD-L1-IN-12 is an orally active and potent selenium-containing small-molecule PD-L1 inhibitor (KD = 9.06 nM). PD-L1-IN-12 can mediate the internalization of PD-L1 and strongly block hPD-1 and hPD-L1 interaction (IC50 = 5.2 nM). PD-L1-IN-12 can be used in colorectal cancer immunology research .
loading...
    loading...
Cat. No.: HY-183607
Research Areas:  

Cancer

SMU-3k is a STING activator and PD-L1 inhibitor, with a PD-L1 IC50 of 106 nM, a KD of 386 nM for human PD-L1, and a KD of 352 nM for murine PD-L1. SMU-3k activates the STING pathway, induces phosphorylation of TBK1 and IRF3, and promotes the expression of IFN-β, IL-6 and CXCL10. SMU-3k blocks the PD-1/PD-L1 interaction, reduces PD-L1 levels and induces PD-L1 internalization. Through dual immunomodulation, SMU-3k exerts synergistic tumor growth inhibitory effects in a mouse colon cancer model. SMU-3k can be used for the research of colon cancer .
loading...
    loading...
Cat. No.: HY-183775
CAS No.: 3114769-08-0
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-1/PD-L1-IN-64 is a PD-1/PD-L1 interaction inhibitor. PD-1/PD-L1-IN-64 induces PD-L1 internalization and oligomerization, enhances T-cell activation, proliferation, and cancer cell elimination. PD-1/PD-L1-IN-64 can be used for the research of cancer .
loading...
    loading...